12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Assessing patient preferences for switching from warfarin to direct oral anticoagulants.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Warfarin remains the most commonly prescribed oral anticoagulant in the United States, but it has disadvantages such as dietary interactions and frequent laboratory monitoring. Direct oral anticoagulants (DOACs) have been introduced as safer and equally effective alternatives to warfarin. This study assessed patient preference for warfarin or DOAC based on a willingness to pay more for potential DOAC benefits. Current warfarin patients with atrial fibrillation or venous thromboembolism enrolled in the University of Utah Health Thrombosis Service were given a one-time electronic survey that assessed preferences between warfarin and DOACs using scenarios comparing effectiveness, safety, and convenience. When DOACs were preferred, patients were asked how much more they would be willing to pay monthly for the perceived advantages associated with DOACs. With 123 completed surveys, 68% of patients preferred to stay on warfarin. No particular factor influenced patient preference (lack of routine laboratory monitoring, lower risks of major bleeding, and fewer dietary interactions). Reduced stroke risk was associated with the highest value (willing to pay an additional $21). Considering all factors, patients preferring DOACs would pay a median $18 extra per month for the additional benefits. Prior exposure to DOACs was associated with preference for DOACs. Many patients currently taking warfarin preferred to stay on warfarin when given the choice, despite DOAC benefits. Willingness to pay extra for DOAC advantages did not exceed $20 in the majority of survey respondents. Previous DOAC exposure influences patient preference and perceived value for DOACs.

          Related collections

          Author and article information

          Journal
          J Thromb Thrombolysis
          Journal of thrombosis and thrombolysis
          Springer Science and Business Media LLC
          1573-742X
          0929-5305
          Nov 2019
          : 48
          : 4
          Affiliations
          [1 ] Department of Pharmacotherapy, University of Utah College of Pharmacy, 30 South 2000 East, Salt Lake City, UT, 84112, USA.
          [2 ] Department of Pharmacotherapy, University of Utah College of Pharmacy, 30 South 2000 East, Salt Lake City, UT, 84112, USA. sara.vazquez@hsc.utah.edu.
          [3 ] University of Utah Health, Thrombosis Service, 50 N Medical Drive Room 1R211, Salt Lake City, UT, 84132, USA. sara.vazquez@hsc.utah.edu.
          [4 ] University of Utah Health, Thrombosis Service, 50 N Medical Drive Room 1R211, Salt Lake City, UT, 84132, USA.
          Article
          10.1007/s11239-019-01915-9
          10.1007/s11239-019-01915-9
          31273515
          517fd038-9f6b-4272-8d67-a5856be7fb99
          History

          Atrial fibrillation,Cost,Direct oral anticoagulant,Preference,Venous thromboembolism,Warfarin

          Comments

          Comment on this article

          scite_
          0
          0
          0
          0
          Smart Citations
          0
          0
          0
          0
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content397

          Cited by8